Objective To analyze the effect of recombinant humanized type Ⅲ collagen combined with type Ⅰ collagen on facial firmness in patients with facial overfilled syndrome. Methods A total of 66 patients with facial overfilled syndrome admitted to our hospital from October 2022 to October 2024 were selected as the research subjects. According to different treatment methods, they were divided into the control group and the experimental group, with 33 patients in each group. The control group was treated with type Ⅰ collagen injection, and the experimental group was treated with recombinant humanized type Ⅲ collagen combined with type Ⅰ collagen injection.The facial firmness, skin physiological indexes, satisfaction and adverse reactions were compared between the two groups. Results The facial firmness scores of the experimental group at 1 week, 1 month, and 3 months after treatment were lower than those of the control group (P <0.05). The skin elasticity R2 value and stratum corneum hydration of the experimental group at 1 month after treatment were higher than those of the control group (P <0.05). The patient satisfaction of the experimental group (96.97%) was higher than that of the control group (75.76%) (P <0.05). The incidence of adverse reactions in the experimental group (6.06%) was lower than that in the control group (30.30%) (P <0.05). Conclusion Recombinant humanized type Ⅲ collagen combined with type Ⅰ collagen injection in the treatment of facial overfilled syndrome can effectively improve facial relaxation, enhance skin physiological status and treatment satisfaction, with good safety, which is worthy of clinical application.